Effects of Nirmatrelvir/ritonavir (paxlovid) on the nervous system: analysis on adverse events released by FDA

DOI record: { "DOI": "10.1080/14740338.2025.2471509", "ISSN": [ "1474-0338", "1744-764X" ], "URL": "http://dx.doi.org/10.1080/14740338.2025.2471509", "alternative-id": [ "10.1080/14740338.2025.2471509" ], "assertion": [ { "label": "Peer Review Statement", "name": "peerreview_statement", "order": 1, "value": "The publishing and review policy for this title is described in its Aims & Scope." }, { "URL": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ieds20", "label": "Aim & Scope", "name": "aims_and_scope_url", "order": 2, "value": "http://www.tandfonline.com/action/journalInformation?show=aimsScope&journalCode=ieds20" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Received", "name": "received", "order": 0, "value": "2024-07-05" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Revised", "name": "revised", "order": 1, "value": "2024-10-17" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Accepted", "name": "accepted", "order": 2, "value": "2024-10-18" }, { "group": { "label": "Publication History", "name": "publication_history" }, "label": "Published", "name": "published", "order": 3, "value": "2025-02-26" } ], "author": [ { "affiliation": [ { "name": "Chongqing Medical University", "place": [ "Chongqing, China" ] } ], "family": "Gao", "given": "Caixia", "sequence": "first" }, { "affiliation": [ { "name": "Chongqing Medical University", "place": [ "Chongqing, China" ] } ], "family": "Liu", "given": "Zhihui", "sequence": "additional" }, { "ORCID": "https://orcid.org/0000-0002-1651-591X", "affiliation": [ { "name": "Chongqing Medical University", "place": [ "Chongqing, China" ] } ], "authenticated-orcid": false, "family": "Zou", "given": "Zhen", "sequence": "additional" }, { "affiliation": [ { "name": "Chongqing Medical University", "place": [ "Chongqing, China" ] } ], "family": "Mao", "given": "Lejiao", "sequence": "additional" }, { "affiliation": [ { "name": "Chongqing Medical University", "place": [ "Chongqing, China" ] } ], "family": "Zhang", "given": "Jun", "sequence": "additional" } ], "container-title": "Expert Opinion on Drug Safety", "container-title-short": "Expert Opinion on Drug Safety", "content-domain": { "crossmark-restriction": true, "domain": [ "www.tandfonline.com" ] }, "created": { "date-parts": [ [ 2025, 2, 27 ] ], "date-time": "2025-02-27T03:03:32Z", "timestamp": 1740625412000 }, "deposited": { "date-parts": [ [ 2025, 2, 27 ] ], "date-time": "2025-02-27T03:03:58Z", "timestamp": 1740625438000 }, "indexed": { "date-parts": [ [ 2025, 2, 27 ] ], "date-time": "2025-02-27T05:33:26Z", "timestamp": 1740634406437, "version": "3.38.0" }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2025, 2, 26 ] ] }, "language": "en", "link": [ { "URL": "https://www.tandfonline.com/doi/pdf/10.1080/14740338.2025.2471509", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "301", "original-title": [], "prefix": "10.1080", "published": { "date-parts": [ [ 2025, 2, 26 ] ] }, "published-online": { "date-parts": [ [ 2025, 2, 26 ] ] }, "publisher": "Informa UK Limited", "reference": [ { "DOI": "10.1056/NEJMoa2208822", "doi-asserted-by": "publisher", "key": "e_1_3_8_3_1" }, { "DOI": "10.1038/s41591-021-01283-z", "article-title": "Post-acute COVID-19 syndrome", "author": "Nalbandian A.", "doi-asserted-by": "crossref", "first-page": "601", "issue": "4", "journal-title": "Nat Med", "key": "e_1_3_8_4_1", "unstructured": "Nalbandian, A., et al., Post-acute COVID-19 syndrome. Nat Med, 2021. 27(4): p. 601–615.", "volume": "27", "year": "2021" }, { "DOI": "10.15585/mmwr.mm7251a1", "doi-asserted-by": "crossref", "key": "e_1_3_8_5_1", "unstructured": "Smith D.J. A. Lambrou and P. Patel SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals. MMWR Morb Mortal Wkly Rep 2023. 72(51): p. 1357–1364." }, { "DOI": "10.1038/s41573-023-00672-y", "article-title": "Therapeutic strategies for COVID-19: progress and lessons learned", "author": "Li G.", "doi-asserted-by": "crossref", "first-page": "449", "issue": "6", "journal-title": "Nat Rev Drug Discov", "key": "e_1_3_8_6_1", "unstructured": "Li, G., et al., Therapeutic strategies for COVID-19: progress and lessons learned. Nat Rev Drug Discov, 2023. 22(6): p. 449–475.", "volume": "22", "year": "2023" }, { "DOI": "10.1021/acs.accounts.2c00735", "doi-asserted-by": "publisher", "key": "e_1_3_8_7_1" }, { "author": "Agarwal A.", "first-page": "m3379", "key": "e_1_3_8_8_1", "unstructured": "Agarwal, A., et al., A living WHO guideline on drugs for covid-19. Bmj, 2020. 370: p. m3379.", "volume-title": "A living WHO guideline on drugs for covid-19", "year": "2020" }, { "key": "e_1_3_8_9_1", "unstructured": "Owen D.R. et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. Science 2021. 374(6575): p. 1586–1593." }, { "DOI": "10.1016/j.jmgm.2021.108042", "article-title": "Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease", "author": "Macchiagodena M.", "doi-asserted-by": "crossref", "first-page": "108042", "journal-title": "J Mol Graph Model", "key": "e_1_3_8_10_1", "unstructured": "Macchiagodena, M., M. Pagliai, and P. Procacci, Characterization of the non-covalent interaction between the PF-07321332 inhibitor and the SARS-CoV-2 main protease. J Mol Graph Model, 2022. 110: p. 108042.", "volume": "110", "year": "2022" }, { "DOI": "10.1056/NEJMoa2118542", "doi-asserted-by": "publisher", "key": "e_1_3_8_11_1" }, { "DOI": "10.15585/mmwr.mm7148e2", "doi-asserted-by": "crossref", "key": "e_1_3_8_12_1", "unstructured": "Shah M.M. et al. Paxlovid Associated with Decreased Hospitalization Rate Among Adults with COVID-19 - United States April-September 2022. MMWR Morb Mortal Wkly Rep 2022. 71(48): p. 1531–1537." }, { "DOI": "10.1007/s40265-022-01692-5", "article-title": "Nirmatrelvir Plus Ritonavir: First Approval", "author": "Lamb Y.N.", "doi-asserted-by": "crossref", "first-page": "585", "issue": "5", "journal-title": "Drugs", "key": "e_1_3_8_13_1", "unstructured": "Lamb, Y.N., Nirmatrelvir Plus Ritonavir: First Approval. Drugs, 2022. 82(5): p. 585–591.", "volume": "82", "year": "2022" }, { "DOI": "10.1021/jacs.3c12678", "article-title": "A Chemical Strategy for the Degradation of the Main Protease of SARS-CoV-2 in Cells", "author": "Sang X.", "doi-asserted-by": "crossref", "first-page": "27248", "issue": "50", "journal-title": "J Am Chem Soc", "key": "e_1_3_8_14_1", "unstructured": "Sang, X., et al., A Chemical Strategy for the Degradation of the Main Protease of SARS-CoV-2 in Cells. J Am Chem Soc, 2023. 145(50): p. 27248–27253.", "volume": "145", "year": "2023" }, { "DOI": "10.1093/cid/ciac180", "article-title": "Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs", "author": "Saravolatz L.D.", "doi-asserted-by": "crossref", "first-page": "165", "issue": "1", "journal-title": "Clin Infect Dis", "key": "e_1_3_8_15_1", "unstructured": "Saravolatz, L.D., S. Depcinski, and M. Sharma, Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs. Clin Infect Dis, 2023. 76(1): p. 165–171.", "volume": "76", "year": "2023" }, { "DOI": "10.1080/14756366.2021.1954919", "article-title": "Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332", "author": "Pavan M.", "doi-asserted-by": "crossref", "first-page": "1646", "issue": "1", "journal-title": "J Enzyme Inhib Med Chem", "key": "e_1_3_8_16_1", "unstructured": "Pavan, M., et al., Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332. J Enzyme Inhib Med Chem, 2021. 36(1): p. 1646–1650.", "volume": "36", "year": "2021" }, { "DOI": "10.3389/fphar.2022.954359", "article-title": "Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system", "author": "Guo Q.", "doi-asserted-by": "crossref", "first-page": "954359", "journal-title": "Front Pharmacol", "key": "e_1_3_8_17_1", "unstructured": "Guo, Q., et al., Adverse drug events in the prevention and treatment of COVID-19: A data mining study on the FDA adverse event reporting system. Front Pharmacol, 2022. 13: p. 954359.", "volume": "13", "year": "2022" }, { "DOI": "10.1002/adma.202311537", "article-title": "ACE2 Receptor-Targeted Inhaled Nanoemulsions Inhibit SARS-CoV-2 and Attenuate Inflammatory Responses", "author": "Wang H.", "doi-asserted-by": "crossref", "first-page": "e2311537", "journal-title": "Adv Mater", "key": "e_1_3_8_18_1", "unstructured": "Wang, H., et al., ACE2 Receptor-Targeted Inhaled Nanoemulsions Inhibit SARS-CoV-2 and Attenuate Inflammatory Responses. Adv Mater, 2024: p. e2311537.", "year": "2024" }, { "DOI": "10.1038/s41579-020-00459-7", "doi-asserted-by": "publisher", "key": "e_1_3_8_19_1" }, { "author": "Fumagalli V.", "key": "e_1_3_8_20_1", "unstructured": "Fumagalli, V. and M. Iannacone, The interplay of drug therapeutics and immune responses to SARS-CoV-2. Cell Mol Immunol, 2023.", "volume-title": "The interplay of drug therapeutics and immune responses to SARS-CoV-2", "year": "2023" }, { "DOI": "10.1093/cid/ciac443", "article-title": "Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients", "author": "Najjar-Debbiny R.", "doi-asserted-by": "crossref", "first-page": "e342", "issue": "3", "journal-title": "Clin Infect Dis", "key": "e_1_3_8_21_1", "unstructured": "Najjar-Debbiny, R., et al., Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients. Clin Infect Dis, 2023. 76(3): p. e342–e349.", "volume": "76", "year": "2023" }, { "DOI": "10.1038/s41392-023-01587-1", "doi-asserted-by": "crossref", "key": "e_1_3_8_22_1", "unstructured": "Zhang Y. et al. A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir. Signal Transduct Target Ther 2023. 8(1): p. 360." }, { "DOI": "10.3389/fphar.2022.938552", "article-title": "Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system", "author": "Jeong E.", "doi-asserted-by": "crossref", "first-page": "938552", "journal-title": "Front Pharmacol", "key": "e_1_3_8_23_1", "unstructured": "Jeong, E., et al., Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system. Front Pharmacol, 2022. 13: p. 938552.", "volume": "13", "year": "2022" }, { "DOI": "10.1016/j.jinf.2022.09.027", "article-title": "Efficacy and safety of Paxlovid for COVID-19:a meta-analysis", "author": "Zheng Q.", "doi-asserted-by": "crossref", "first-page": "66", "issue": "1", "journal-title": "J Infect", "key": "e_1_3_8_24_1", "unstructured": "Zheng, Q., et al., Efficacy and safety of Paxlovid for COVID-19:a meta-analysis. J Infect, 2023. 86(1): p. 66–117.", "volume": "86", "year": "2023" }, { "DOI": "10.1002/jmv.28471", "article-title": "Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: A systematic review and meta-analysis", "author": "Cheema H.A.", "doi-asserted-by": "crossref", "first-page": "e28471", "issue": "2", "journal-title": "J Med Virol", "key": "e_1_3_8_25_1", "unstructured": "Cheema, H.A., et al., Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: A systematic review and meta-analysis. J Med Virol, 2023. 95(2): p. e28471.", "volume": "95", "year": "2023" }, { "DOI": "10.1080/07853890.2022.2034936", "article-title": "Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis", "author": "Wen W.", "doi-asserted-by": "crossref", "first-page": "516", "issue": "1", "journal-title": "Ann Med", "key": "e_1_3_8_26_1", "unstructured": "Wen, W., et al., Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. Ann Med, 2022. 54(1): p. 516–523.", "volume": "54", "year": "2022" }, { "DOI": "10.1002/ohn.278", "doi-asserted-by": "publisher", "key": "e_1_3_8_27_1" }, { "DOI": "10.1002/jmv.28732", "article-title": "Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis", "author": "Tian F.", "doi-asserted-by": "crossref", "first-page": "e28732", "issue": "4", "journal-title": "J Med Virol", "key": "e_1_3_8_28_1", "unstructured": "Tian, F., Z. Chen, and Q. Feng, Nirmatrelvir-ritonavir compared with other antiviral drugs for the treatment of COVID-19 patients: A systematic review and meta-analysis. J Med Virol, 2023. 95(4): p. e28732.", "volume": "95", "year": "2023" }, { "key": "e_1_3_8_29_1", "unstructured": "Pfizer. Nirmatrelvir/ritonavir Paxlovid. 2022-2-7]; Available from: https://www.pfizermedicalinformation.cn/products/package-insert/paxlovid." }, { "DOI": "10.1080/14740338.2022.2045945", "doi-asserted-by": "publisher", "key": "e_1_3_8_30_1" }, { "author": "Deng Z.", "key": "e_1_3_8_31_1", "unstructured": "Deng, Z., et al., Psychiatric disorders associated with PCSK9 inhibitors: A real-world, pharmacovigilance study. CNS Neurosci Ther, 2023.", "volume-title": "Psychiatric disorders associated with PCSK9 inhibitors: A real-world, pharmacovigilance study", "year": "2023" }, { "key": "e_1_3_8_32_1", "unstructured": "FDA. FDA Adverse Event Reporting System (FAERS): Latest Quarterly Data Files. 2004-1]; Available from: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-latest-quarterly-data-files." }, { "DOI": "10.1001/jamaneurol.2020.1127", "doi-asserted-by": "crossref", "key": "e_1_3_8_33_1", "unstructured": "Mao L. et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan China. JAMA Neurol 2020. 77(6): p. 683–690." }, { "DOI": "10.1038/s41591-022-02001-z", "article-title": "Long-term neurologic outcomes of COVID-19", "author": "Xu E.", "doi-asserted-by": "crossref", "first-page": "2406", "issue": "11", "journal-title": "Nat Med", "key": "e_1_3_8_34_1", "unstructured": "Xu, E., Y. Xie, and Z. Al-Aly, Long-term neurologic outcomes of COVID-19. Nat Med, 2022. 28(11): p. 2406–2415.", "volume": "28", "year": "2022" }, { "DOI": "10.1016/S2215-0366(22)00260-7", "article-title": "Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients", "author": "Taquet M.", "doi-asserted-by": "crossref", "first-page": "815", "issue": "10", "journal-title": "Lancet Psychiatry", "key": "e_1_3_8_35_1", "unstructured": "Taquet, M., et al., Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. Lancet Psychiatry, 2022. 9(10): p. 815–827.", "volume": "9", "year": "2022" }, { "DOI": "10.1038/s41586-022-05542-y", "article-title": "SARS-CoV-2 infection and persistence in the human body and brain at autopsy", "author": "Stein S.R.", "doi-asserted-by": "crossref", "first-page": "758", "issue": "7941", "journal-title": "Nature", "key": "e_1_3_8_36_1", "unstructured": "Stein, S.R., et al., SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature, 2022. 612(7941): p. 758–763.", "volume": "612", "year": "2022" }, { "DOI": "10.1002/jcla.24403", "article-title": "Neurological manifestations in patients with COVID-19: A systematic review and meta-analysis", "author": "Mahdizade Ari M.", "doi-asserted-by": "crossref", "first-page": "e24403", "issue": "5", "journal-title": "J Clin Lab Anal", "key": "e_1_3_8_37_1", "unstructured": "Mahdizade Ari, M., et al., Neurological manifestations in patients with COVID-19: A systematic review and meta-analysis. J Clin Lab Anal, 2022. 36(5): p. e24403.", "volume": "36", "year": "2022" }, { "DOI": "10.1016/j.dsx.2021.04.026", "article-title": "Cerebral venous thrombosis in COVID-19", "author": "Ghosh R.", "doi-asserted-by": "crossref", "first-page": "1039", "issue": "3", "journal-title": "Diabetes Metab Syndr", "key": "e_1_3_8_38_1", "unstructured": "Ghosh, R., et al., Cerebral venous thrombosis in COVID-19. Diabetes Metab Syndr, 2021. 15(3): p. 1039–1045.", "volume": "15", "year": "2021" }, { "DOI": "10.1093/brain/awac270", "doi-asserted-by": "crossref", "key": "e_1_3_8_39_1", "unstructured": "Soung A.L. et al. COVID-19 induces CNS cytokine expression and loss of hippocampal neurogenesis. Brain 2022. 145(12): p. 4193–4201." }, { "DOI": "10.1073/pnas.2200960119", "article-title": "Morphological, cellular, and molecular basis of brain infection in COVID-19 patients", "author": "Crunfli F.", "doi-asserted-by": "crossref", "first-page": "e2200960119", "issue": "35", "journal-title": "Proc Natl Acad Sci U S A", "key": "e_1_3_8_40_1", "unstructured": "Crunfli, F., et al., Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc Natl Acad Sci U S A, 2022. 119(35): p. e2200960119.", "volume": "119", "year": "2022" }, { "DOI": "10.1016/j.bbi.2021.12.007", "article-title": "SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties", "author": "Frank M.G.", "doi-asserted-by": "crossref", "first-page": "267", "journal-title": "Brain Behav Immun", "key": "e_1_3_8_41_1", "unstructured": "Frank, M.G., et al., SARS-CoV-2 spike S1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of PAMP-like properties. Brain Behav Immun, 2022. 100: p. 267–277.", "volume": "100", "year": "2022" }, { "key": "e_1_3_8_42_1", "unstructured": "Needham E.J. et al. Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses. Brain 2022. 145(11): p. 4097–4107." }, { "key": "e_1_3_8_43_1", "unstructured": "Paterson R.W. et al. The emerging spectrum of COVID-19 neurology: clinical radiological and laboratory findings. Brain 2020. 143(10): p. 3104–3120." }, { "DOI": "10.1016/S2215-0366(20)30203-0", "article-title": "Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic", "author": "Rogers J.P.", "doi-asserted-by": "crossref", "first-page": "611", "issue": "7", "journal-title": "Lancet Psychiatry", "key": "e_1_3_8_44_1", "unstructured": "Rogers, J.P., et al., Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry, 2020. 7(7): p. 611–627.", "volume": "7", "year": "2020" }, { "article-title": "Neuropsychiatric aspects of long COVID: A comprehensive review", "author": "Kubota T.", "journal-title": "Psychiatry Clin Neurosci", "key": "e_1_3_8_45_1", "unstructured": "Kubota, T., N. Kuroda, and D. Sone, Neuropsychiatric aspects of long COVID: A comprehensive review. Psychiatry Clin Neurosci, 2022.", "year": "2022" }, { "author": "Hartung T.J.", "first-page": "101651", "key": "e_1_3_8_46_1", "unstructured": "Hartung, T.J., et al., Fatigue and cognitive impairment after COVID-19: A prospective multicentre study. EClinicalMedicine, 2022. 53: p. 101651.", "volume-title": "Fatigue and cognitive impairment after COVID-19: A prospective multicentre study", "year": "2022" }, { "DOI": "10.1038/s41380-022-01632-5", "article-title": "Selective visuoconstructional impairment following mild COVID-19 with inflammatory and neuroimaging correlation findings", "author": "de Paula J.J.", "doi-asserted-by": "crossref", "first-page": "553", "issue": "2", "journal-title": "Mol Psychiatry", "key": "e_1_3_8_47_1", "unstructured": "de Paula, J.J., et al., Selective visuoconstructional impairment following mild COVID-19 with inflammatory and neuroimaging correlation findings. Mol Psychiatry, 2023. 28(2): p. 553–563.", "volume": "28", "year": "2023" }, { "article-title": "Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS", "author": "Li M.", "journal-title": "Pharmaceuticals (Basel)", "key": "e_1_3_8_48_1", "unstructured": "Li, M., et al., Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS. Pharmaceuticals (Basel), 2022. 15(12).", "year": "2022" }, { "DOI": "10.1001/jamanetworkopen.2022.7970", "doi-asserted-by": "crossref", "key": "e_1_3_8_49_1", "unstructured": "Conti V. et al. Identification of Drug Interaction Adverse Events in Patients With COVID-19: A Systematic Review. JAMA Netw Open 2022. 5(4): p. e227970." }, { "DOI": "10.1038/s41598-021-91953-2", "article-title": "Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain", "author": "Cantudo-Cuenca M.D.", "doi-asserted-by": "crossref", "first-page": "12414", "issue": "1", "journal-title": "Sci Rep", "key": "e_1_3_8_50_1", "unstructured": "Cantudo-Cuenca, M.D., et al., Drug-drug interactions between treatment specific pharmacotherapy and concomitant medication in patients with COVID-19 in the first wave in Spain. Sci Rep, 2021. 11(1): p. 12414.", "volume": "11", "year": "2021" }, { "DOI": "10.1080/17425255.2024.2339397", "article-title": "Adverse events related to drug-drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era: a systematic review", "author": "Conti V.", "doi-asserted-by": "crossref", "first-page": "275", "issue": "4", "journal-title": "Expert Opin Drug Metab Toxicol", "key": "e_1_3_8_51_1", "unstructured": "Conti, V., et al., Adverse events related to drug-drug interactions in COVID-19 patients. A persistent concern in the post-pandemic era: a systematic review. Expert Opin Drug Metab Toxicol, 2024. 20(4): p. 275–292.", "volume": "20", "year": "2024" }, { "DOI": "10.1007/s00228-022-03370-7", "article-title": "COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed", "author": "Yalcin N.", "doi-asserted-by": "crossref", "first-page": "1697", "issue": "10", "journal-title": "Eur J Clin Pharmacol", "key": "e_1_3_8_52_1", "unstructured": "Yalcin, N. and K. Allegaert, COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir/ritonavir is co-prescribed. Eur J Clin Pharmacol, 2022. 78(10): p. 1697–1701", "volume": "78", "year": "2022" } ], "reference-count": 50, "references-count": 50, "relation": {}, "resource": { "primary": { "URL": "https://www.tandfonline.com/doi/full/10.1080/14740338.2025.2471509" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [], "subtitle": [], "title": "Effects of Nirmatrelvir/ritonavir (paxlovid) on the nervous system: analysis on adverse events released by FDA", "type": "journal-article", "update-policy": "https://doi.org/10.1080/tandf_crossmark_01" }